TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02197403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1\~1.0mcg/Kg infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1\~1.0mcg/Kg infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 25\~75mcg/kg/min continuous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 25\~75mcg/kg/min continuous infusion
Study: NCT01567904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)~Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)~Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)~Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)~Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)~Subcutaneous injection
Study: NCT04096053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEACHH
Description: See arm/group description.
Study: NCT00217308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacilli GR-1 and RC-14
Description: Probiotic Lactobacilli will be compared to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacilli GR-1 and RC-14
Description: Probiotic Lactobacilli will be compared to placebo
Study: NCT02486276

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study: NCT04391634

Intervention type: OTHER
Group type: OTHER
Intervention: volume guarantee
Description: volume guarantee assist-control mechanical ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: pressure-controlled
Description: pressure-controlled assist-control mechanical ventilation
Study: NCT04189705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCT-SR
Description: Rebamipide 150mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCT-SR
Description: Rebamipide 150mg
Study: NCT02715349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: 3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
Study: NCT04189705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucosta Tab.
Description: Rebamipide 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucosta Tab.
Description: Rebamipide 100mg
Study: NCT04950829

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional brackets
Description: These brackets are used in a conventional way, where the orthodontist used to apply elastic parts to engage the arch to the slot of the brackets.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Description: These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-Ligating Brackets with flapless corticotomy
Description: These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.~Flapless corticotomy will be performed in order to stimulate acceleration in tooth movement during the orthodontic treatment in this group only.
Study: NCT02316860

Intervention type: OTHER
Group type: OTHER
Intervention: Passive tilt test
Description: Passive tilt test (without pharmacological provocation). After a horizontal supine rest period of 5 min, the tilt table was inclined at 60° head-up position for 30 min. A positive response was defined according to the European Society of Cardiology guidelines for the diagnosis and management of syncope
Study: NCT01619839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-181
Study: NCT02093000

Intervention type: DRUG
Intervention: Bevacizumab
Description: Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.
Study: NCT00944398

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc fortified food
Description: Daily consumption

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc supplement
Description: Liquid supplement containing zinc sulfate
Study: NCT01619839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-181

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181
Study: NCT00088530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone
Description: Day 1: pixantrone (150 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
Description: Day 1: cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
Study: NCT02539641

Intervention type: RADIATION
Group type: OTHER
Intervention: Gastric emptying scintigraphy
Description: Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)

Intervention type: RADIATION
Group type: OTHER
Intervention: Gastric emptying scintigraphy
Description: Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)

Intervention type: RADIATION
Group type: OTHER
Intervention: Gastric emptying scintigraphy
Description: Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)
Study: NCT00944398

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Liquid placebo supplement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo supplement
Description: Liquid placebo supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-fortified food
Description: Non-fortified complementary food.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-fortified food
Description: Non-fortified complementary food.
Study: NCT02539641

Intervention type: RADIATION
Group type: OTHER
Intervention: Gastric emptying scintigraphy
Description: Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)

Intervention type: RADIATION
Group type: OTHER
Intervention: Gastric emptying scintigraphy
Description: Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of gut hormones
Description: Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of gut hormones
Description: Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of gut hormones
Description: Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of gut hormones
Description: Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.
Study: NCT00878163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT01176032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg film coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5mg was given to patients who did not achieve the required blood pressure (\<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (\<140/90 mmHg) was still not achieved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5mg was given to patients who did not achieve the required blood pressure (\<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (\<140/90 mmHg) was still not achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (\<140/90 mmHg) had not been reached.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (\<140/90 mmHg) had not been reached.
Study: NCT01380223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: I.V. infusion of placebo for 8 hr
Study: NCT01806103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antimicrobial Stewardship Bundle
Description: Guidelines, Education, Audit and Feedback
Study: NCT01380223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: I.V. infusion of placebo for 8 hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: I.V. infusion of placebo for 8 hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: I.V. infusion of placebo for 8 hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.005 mg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.015 mg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.0625 mg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.25 mg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr
Study: NCT02728869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat Stable Rotavirus (HSRV) Vaccine
Description: It is a lyophilized live attenuated pentavalent (G1-G4 and P1\[8\]) heat-stable rotavirus vaccine (HSRV) comprising of all the five rotavirus strains as in licensed RotaTeq® vaccine for protection against rotavirus infection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat Stable Rotavirus (HSRV) Vaccine
Description: It is a lyophilized live attenuated pentavalent (G1-G4 and P1\[8\]) heat-stable rotavirus vaccine (HSRV) comprising of all the five rotavirus strains as in licensed RotaTeq® vaccine for protection against rotavirus infection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Heatstable Rotavirus vaccine
Description: It is a lyophilized formulation comprising of all the inactive ingredients as in heat stable rotavirus vaccine without any rotavirus
Study: NCT01380223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 1.0 mg/kg/hr
Study: NCT02728869

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq®
Description: It is a pentavalent human-bovine (WC3) reassortant live-attenuated, oral vaccine developed by Merck Research Co., West Point, Pennsylvania, USA. This vaccine contains five live reassortant rotaviruses. Four reassortant rotaviruses express the VP7 protein (G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein (P7\[5\]) from bovine rotavirus parent strain WC3. The fifth reassortant virus expresses the attachment protein (P1A\[8\]) from the human rotavirus parent strain and the outer capsid protein G6 from the bovine rotavirus parent strain.
Study: NCT00704379

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an inactive substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline and placebo will be given in a double blind fashion via an equal number of identical tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention. Blood samples will be obtained randomly, one during the first and one during the second trimesters of the protocol.
Study: NCT01638234

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: melatonin 3 mg tab 1 tab po hs for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch pill
Study: NCT02479048

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test meal 1
Description: High fat meal (HF) with ½ avocado (\~68g), matched to CM for energy content; not matched for macronutrient content or type (e.g., fat type).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test meal 2
Description: High fat meal (HF) with 1 avocado (\~136g) matched for energy but not macronutrient content or type.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Meal (CM)
Description: High carbohydrate, high saturated fat control meal (CM) without avocado.
Study: NCT01380223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.75 mg/kg/hr (dose reduced)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omecamtiv mecarbil
Description: I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.625 mg/kg/hr (dose reduced)
Study: NCT02845817

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative research
Description: Semi-structured interviews
Study: NCT03787186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690 film-coated tablets
Description: a single oral dose of GLPG1690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GLPG1690 solution for infusion
Description: a 15-minute IV infusion \[14C\]-GLPG1690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GLPG1690 capsules
Description: single oral dose of \[14C\]-GLPG1690
Study: NCT06249685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral hearing devices
Description: Three week trial while wearing bilateral hearing devices.
Study: NCT02461381

Intervention type: OTHER
Intervention: not intervention
Description: This is a cross-sectional study for estimation of diagnostic performance.
Study: NCT04610047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norketotifen
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT01379417

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic supplementation
Description: 1 capsule per day, from inclusion to 4 or 6 weeks after inclusion

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplementation
Description: 1 capsule per day, from inclusion to 4 or 6 weeks after inclusion

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplementation
Description: 1 capsule per day, from inclusion to 4 or 6 weeks after inclusion

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplementation
Description: 1 capsule per day, from inclusion to 4 or 6 weeks after inclusion
Study: NCT03669367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Injection
Description: Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxycloroquina
Description: oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months)
Study: NCT00596986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine 30mg up to 120mg per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Analysis System of Psychotherapy
Description: Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
Study: NCT03882892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovastatin
Description: Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atovastatin
Description: Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matched to ezetimibe
Study: NCT01665196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Intravenous injection of single dose of 18F-FDG before treatment and after 4-week treatment, respectively.
Study: NCT01175863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Grey scale intravascular ultrasound (Galaxy or Virtual histology-Intravascular Ultrasound)
Description: minimal lumen area on Intravascular ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure wire(Radi Medical Systems)
Description: Fractional flow reserve measured by pressure wire
Study: NCT02525471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 23 weeks.~In addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase.
Study: NCT02907424

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2 months of treatment
Description: standard 2 months of treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2 months of treatment
Description: standard 2 months of treatment
Study: NCT00519519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: intravenous 80mg bolus followed by 8mg / hr for 3 days
Study: NCT04261998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Service-learning program
Description: Intervention group will perform a service-learning program with real patients with heart transplantation, and will have to perform a physical therapy program adapted to a real patient. Two meetings will be performed in order to establish groups, explain the project and search information based on evidence in scientific databases. In addition, three meetings with patients will be stated in order to establish the adapted program based on the real patient's needs and characteristics.